Related references
Note: Only part of the references are listed.Prognostic nomograms based on immune scores for head-neck squamous cell carcinoma patients
Wenfei Li et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2021)
Updates in Cardiac Amyloidosis Diagnosis and Treatment
Lily K. Stern et al.
CURRENT ONCOLOGY REPORTS (2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
E. Kastritis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable
Jonah Rubin et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review
Morie A. Gertz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis
Jithma P. Abeykoon et al.
LEUKEMIA (2019)
AL amyloidosis: advances in diagnostics and treatment
Romana Rysava
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
Yue Zhang et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms
Carsten Nieder et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2018)
Nomograms are key decision-making tools in prostate cancer radiation therapy
Sarah Caulfield et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Cardiac Amyloidosis: Diagnosis and Treatment Strategies
Mirela Tuzovic et al.
CURRENT ONCOLOGY REPORTS (2017)
First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis
Taimur Sher et al.
BLOOD (2016)
Nomograms in oncology: more than meets the eye
Vinod P. Balachandran et al.
LANCET ONCOLOGY (2015)
Guidelines on the management of AL amyloidosis
Ashutosh D. Wechalekar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Shira Dinner et al.
HAEMATOLOGICA (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis
Umit Tapan et al.
BLOOD (2010)
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
Giovanni Palladini et al.
ANNALS OF HEMATOLOGY (2009)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
